# FDA 483 - Barbara E. Rizzardi, MD - December 02, 2022

Source: https://www.globalkeysolutions.net/records/483/barbara-e-rizzardi-md/6f4908c4-8e87-4e32-bcf9-4c4962d6a093

> FDA 483 for Barbara E. Rizzardi, MD on December 02, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Barbara E. Rizzardi, MD
- Inspection Date: 2022-12-02
- Product Type: drugs
- Office Name: Denver District Office
- Summary: An FDA inspection of Barbara E. Rizzardi, MD, a Principal Investigator in West Jordan, UT, revealed a significant failure to conduct an investigation in accordance with the signed statement of investigator. Specifically, a subject was improperly enrolled in a clinical trial despite having positive serology tests that violated exclusion criteria. This indicates a serious lapse in adherence to study protocols and investigator responsibilities.

## Related Officers

- [Theressa B. Smith](https://www.globalkeysolutions.net/people/theressa-b-smith/80f0c339-7eac-4c73-b9f6-ecb368738fe6)

Company: https://www.globalkeysolutions.net/companies/barbara-e-rizzardi-md/764fb957-5950-45a7-9acb-1984d71277cc

Office: https://www.globalkeysolutions.net/offices/denver-district-office/93b79063-390c-4759-af6c-5da7e388face